Skip to content

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez, Merve Atli, James C Bennett, Megan Croal, Charles DeBattista, Boadie W Dunlop, David Feifel, David J Hellerstein, Muhammad Ishrat Husain, John R. Kelly, Molly Lennard-Jones, Rasmus W Licht, Lindsey Marwood, Sunil Mistry, Tomáš Páleníček, Ozlem Redjep, Dimitris Repantis, Robert A Schoevers, Batya Septimus, Hollie Simmons, Jair C Soares, Metten Somers, Susan C Stansfield, Jessica R Stuart, Hannah H Tadley, Nisha K Thiara, Joyce Tsai, Mourad Wahba, Sam Williams, Rachel I. Winzer, Allan H. Young, Matthew B Young, Sid Zisook, Ekaterina Malievskaia

Journal of Affective Disorders February 3, 2023 DOI: 10.1016/j.jad.2023.01.108 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized clinical trial Peer reviewed
Population People with treatment-resistant depression
Intervention Psilocybin
Dose 25 mg, 10 mg
Duration Three weeks after dosing
Topics Anxiety Depression Psilocybin
Keywords Antidepressant Patient-reported outcomes Psychedelic treatment Hallucinogenic medicine Treatment-resistant depression trd Refractory depression Clinical trials
Citations 168
Key findings Psilocybin 25 mg and, to a lesser degree, 10 mg improved patient-reported depression severity, anxiety, affect, and functioning three weeks after dosing.

Abstract

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

Comparable studies

Other randomized controlled trials on psilocybin for anxiety, most cited first.

Study Year Design Participants
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies Healthy human subjects 2010 Pooled analysis of double-blind placebo-controlled experimental studies n = 110

Citations in the library

Cited by 138

and 133 more in the library

Cites 10

and 5 more in the library

Related reading

Explore topics

Anxiety Depression Psilocybin

By condition and practice

Psilocybin for anxiety Psilocybin for depression